Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
Public ClinicalTrials.gov record NCT01684163. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
GLYX-13 is a NMDA receptor glycine site partial agonist being studied in subjects with major depressive disorder (depression) who have responded inadequately to another antidepressant drug during the current episode. This trial will assess the effects of GLYX-13 on depression when added to another antidepressant drug that the patient is already taking.
Study identification
- NCT ID
- NCT01684163
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 369 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2012 (Type not available)
- Primary completion
- Apr 2014 (Actual)
- Completion
- Jun 2014 (Actual)
- Last update posted
- Mar 17, 2016
2012 – 2014
United States locations
- U.S. sites
- 26
- U.S. states
- 16
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama Office of Psychiatric Clinical Research | Birmingham | Alabama | 35294 | — |
| Pharmacology Research Institute | Encino | California | 91316 | — |
| Pharmacology Research Institute | Los Alamitos | California | 90720 | — |
| Pacific Institute of Medical Research | Los Angeles | California | 90024 | — |
| Pharmacology Research Institute | Newport Beach | California | 92660 | — |
| Artemis Institute for Clinical Research | San Diego | California | 92103 | — |
| Sarkis Clinical Trials | Gainesville | Florida | 32607 | — |
| Atlanta Center for Medical Research | Atlanta | Georgia | 30308 | — |
| Atlanta Institute of Medicine and Research | Atlanta | Georgia | 30328 | — |
| Chicago Research Center | Chicago | Illinois | 60634 | — |
| Evanston Premier Healthcare Research, LLC | Northbrook | Illinois | 60201 | — |
| Indiana University Health Neuroscience Center | Indianapolis | Indiana | 46201 | — |
| University of Kansas | Wichita | Kansas | 67211 | — |
| PharmaSite Research , Inc. | Baltimore | Maryland | 21208 | — |
| Bostin Clinical Trials, Inc. | Roslindale | Massachusetts | 02131 | — |
| CRI Lifetree | Marlton | New Jersey | 08054 | — |
| Global Medical Institutes LLC | Princeton | New Jersey | 08540 | — |
| Clinilabs, Inc. | New York | New York | 10019 | — |
| Michael R Liebowitz MD | New York | New York | 10128 | — |
| Finger Lake Clinical Research | Rochester | New York | 14618 | — |
| Summit Research Network (Oregon), Inc. | Portland | Oregon | 97210 | — |
| Lehigh Center for Clinical Research | Allentown | Pennsylvania | 18104 | — |
| CRI Lifetree | Phildadelphia | Pennsylvania | 19139 | — |
| University of Texas Southwestern Medical Center of Dallas | Dallas | Texas | 75235 | — |
| CRI Lifetree | Salt Lake City | Utah | 84106 | — |
| Summit Research Network | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01684163, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 17, 2016 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01684163 live on ClinicalTrials.gov.